Baicheng Pharmaceutical (301096.SZ) and Zhongshen Innovation reached an authorized cooperation on the innovative drug BIOS-0629 project

Zhitongcaijing · 11/21/2025 11:49

Zhitong Finance App News, Baicheng Pharmaceutical (301096.SZ) announced that the company and Zhejiang Zhongshen Innovative Pharmaceutical Technology Co., Ltd. (“Zhongshen Innovation”) reached an exclusive licensing cooperation in Greater China on the BIOS-0629 Class 1 innovative drug project and signed a “Technology Development Cooperation Agreement” and supplementary agreement.

Regarding the development progress of the BIOS-0629 project, it is currently in the PCC stage, and its indications are: solid tumors. According to the agreement, the company will be responsible for research and development, clinical trials, and registration of cooperative products. Zhongshen Innovation is responsible for R&D transformation, post-marketing production and sales, and market expansion in the Greater China region. After the contract was signed, Gods Innovation paid a milestone payment of 300 million yuan based on the R&D node. After the cooperative products are listed in Greater China, the company also enjoys 10% commission income from sales.

According to the announcement, the two sides will rely on their respective resources and technical advantages in innovative drug research and development to deepen collaborative innovation, accelerate the transformation process of the BIOS-0629 project from laboratory results to clinical application, and jointly promote innovative results.